These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 17968031)

  • 1. Hormonal markers in breast cancer: coexpression, relationship with pathologic characteristics, and risk factor associations in a population-based study.
    Yang XR; Pfeiffer RM; Garcia-Closas M; Rimm DL; Lissowska J; Brinton LA; Peplonska B; Hewitt SM; Cartun RW; Mandich D; Sasano H; Evans DB; Sutter TR; Sherman ME
    Cancer Res; 2007 Nov; 67(21):10608-17. PubMed ID: 17968031
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of a basal-like subtype of breast ductal carcinoma in situ.
    Livasy CA; Perou CM; Karaca G; Cowan DW; Maia D; Jackson S; Tse CK; Nyante S; Millikan RC
    Hum Pathol; 2007 Feb; 38(2):197-204. PubMed ID: 17234468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer.
    Rhee J; Han SW; Oh DY; Kim JH; Im SA; Han W; Park IA; Noh DY; Bang YJ; Kim TY
    BMC Cancer; 2008 Oct; 8():307. PubMed ID: 18947390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical importance of estrogen receptor-beta evaluation in breast cancer patients treated with adjuvant tamoxifen therapy.
    Honma N; Horii R; Iwase T; Saji S; Younes M; Takubo K; Matsuura M; Ito Y; Akiyama F; Sakamoto G
    J Clin Oncol; 2008 Aug; 26(22):3727-34. PubMed ID: 18669459
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFR.
    Hicks DG; Short SM; Prescott NL; Tarr SM; Coleman KA; Yoder BJ; Crowe JP; Choueiri TK; Dawson AE; Budd GT; Tubbs RR; Casey G; Weil RJ
    Am J Surg Pathol; 2006 Sep; 30(9):1097-104. PubMed ID: 16931954
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of a chemoprevention cohort from a population of women at high risk for breast cancer.
    Fabian CJ; Kamel S; Zalles C; Kimler BF
    J Cell Biochem Suppl; 1996; 25():112-22. PubMed ID: 9027607
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
    Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
    Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Obesity and risk of the less commonly diagnosed subtypes of breast cancer.
    Stark A; Schultz D; Kapke A; Nadkarni P; Burke M; Linden M; Raju U
    Eur J Surg Oncol; 2009 Sep; 35(9):928-35. PubMed ID: 19121564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical, histopathologic, and immunohistochemical features of microglandular adenosis and transition into in situ and invasive carcinoma.
    Khalifeh IM; Albarracin C; Diaz LK; Symmans FW; Edgerton ME; Hwang RF; Sneige N
    Am J Surg Pathol; 2008 Apr; 32(4):544-52. PubMed ID: 18300793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of estrogen receptor alpha and beta and progesterone receptor expression and correlation with clinicopathologic factors and proliferative marker Ki-67 in breast cancers.
    Rosa FE; Caldeira JR; Felipes J; Bertonha FB; Quevedo FC; Domingues MA; Moraes Neto FA; Rogatto SR
    Hum Pathol; 2008 May; 39(5):720-30. PubMed ID: 18234277
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical significance of basal-like subtype in triple-negative breast cancer.
    Yamamoto Y; Ibusuki M; Nakano M; Kawasoe T; Hiki R; Iwase H
    Breast Cancer; 2009; 16(4):260-7. PubMed ID: 19701681
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Coordinated expression of oestrogen and androgen receptors in HER2-positive breast carcinomas: impact on proliferative activity.
    Lin Fde M; Pincerato KM; Bacchi CE; Baracat EC; Carvalho FM
    J Clin Pathol; 2012 Jan; 65(1):64-8. PubMed ID: 22039288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors associated with estrogen receptors-alpha (ER-alpha) and -beta (ER-beta) and progesterone receptor abundance in obese and non obese pre- and post-menopausal women.
    Meza-Muñoz DE; Fajardo ME; Pérez-Luque EL; Malacara JM
    Steroids; 2006 Jun; 71(6):498-503. PubMed ID: 16566954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of HER2 and estrogen receptor alpha depends upon nuclear localization of Y-box binding protein-1 in human breast cancers.
    Fujii T; Kawahara A; Basaki Y; Hattori S; Nakashima K; Nakano K; Shirouzu K; Kohno K; Yanagawa T; Yamana H; Nishio K; Ono M; Kuwano M; Kage M
    Cancer Res; 2008 Mar; 68(5):1504-12. PubMed ID: 18316615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group.
    Kyndi M; Sørensen FB; Knudsen H; Overgaard M; Nielsen HM; Overgaard J;
    J Clin Oncol; 2008 Mar; 26(9):1419-26. PubMed ID: 18285604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The expression pattern of MUC1 (EMA) is related to tumour characteristics and clinical outcome of invasive ductal breast carcinoma.
    van der Vegt B; de Roos MA; Peterse JL; Patriarca C; Hilkens J; de Bock GH; Wesseling J
    Histopathology; 2007 Sep; 51(3):322-35. PubMed ID: 17645748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Breast cancer risk factors according to joint estrogen receptor and progesterone receptor status.
    Rusiecki JA; Holford TR; Zahm SH; Zheng T
    Cancer Detect Prev; 2005; 29(5):419-26. PubMed ID: 16185815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of breast cancer subtypes by quantitative assessment of biological parameters: relationship with clinicopathological characteristics, biological features and prognosis.
    Del Casar JM; Martín A; García C; Corte MD; Alvarez A; Junquera S; González LO; Bongera M; García-Muñiz JL; Allende MT; Vizoso F
    Eur J Obstet Gynecol Reprod Biol; 2008 Dec; 141(2):147-52. PubMed ID: 18768247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of aromatase expression in cervical carcinomas: effects of endogenous estrogen on cervical cancer cell proliferation.
    Nair HB; Luthra R; Kirma N; Liu YG; Flowers L; Evans D; Tekmal RR
    Cancer Res; 2005 Dec; 65(23):11164-73. PubMed ID: 16322267
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GATA3 expression in estrogen receptor alpha-negative endometrial carcinomas identifies aggressive tumors with high proliferation and poor patient survival.
    Engelsen IB; Stefansson IM; Akslen LA; Salvesen HB
    Am J Obstet Gynecol; 2008 Nov; 199(5):543.e1-7. PubMed ID: 18599012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.